Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + methotrexate + vandetanib
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of metronomic cyclophosphamide (50 mg daily), methotrexate (2.5 mg days 1-2 weekly), and vandetanib (100-300 mg daily, with 200 mg being the maximum tolerated dose). This regimen combines traditional chemotherapeutic agents administered in a metronomic schedule with a multi-targeted tyrosine kinase inhibitor that has antiangiogenic properties. The combination has been studied in metastatic breast cancer patients with modest clinical activity observed in heavily pretreated populations.
02
Targets
DNADHFR (Dihydrofolate reductase)EGFR (Epidermal growth factor receptor)MRP3 (Multidrug resistance-associated protein 3)RET (Rearranged during transfection receptor tyrosine kinase)SHMT2 (Serine hydroxymethyltransferase 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)EPH (EPH receptor family)PTK6 (Protein-tyrosine kinase 6)SFK (SRC family kinases)TEK (Tie2)
Beyond the preview
Go deeper on cyclophosphamide + methotrexate + vandetanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + methotrexate + vandetanib.